Davis A Brian reported grant involving an undisclosed number of derivative units of Grace Therapeutics, Inc. at $0.00 on Sep 17, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Sep 21, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
—Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
12,200Direct
Trade date
Sep 17, 2026Grant
Filed
Sep 21, 2026, 4:20 PM ET4-day reporting delay
Accession
0001140361-26-037245Code A · Transaction 226624
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing sharesThe filing did not provide usable transaction shares.

GRCE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GRCE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +1.4%1w ago +7.1%1d ago +1.9%
Returns since7d +1%30d −6.2%90d180d1y

Footnotes in full

F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.